Celltrion Chairman Suh Jeong-jin has officially launched the company’s entry into the Contract Development and Manufacturing Organization (CDMO) business. He also announced an ambitious goal of achieving KRW 10 trillion in revenue by 2027.

During an investor relations (IR) meeting held in Hong Kong on the 27th, Suh stated, “We have prepared approximately KRW 1.5 trillion in internal funds to establish a CDMO subsidiary next month, and we plan to begin constructing production facilities in Korea next year.”

He added, “We will recruit additional highly skilled personnel and establish research laboratories in the United States, India, and Europe. From 2028, we will begin full-scale commercial operations, generating revenue. We aim to achieve sales of over KRW 100 billion per 10,000 liters of production capacity.”

Suh further explained that to expedite the establishment of facilities, the company plans to construct a plant with a capacity of up to 200,000 liters in Korea. He stated, “Building a 100,000-liter facility requires an investment of KRW 700 billion, so a total investment of approximately KRW 1.5 trillion is needed for 200,000 liters. If the capacity exceeds 200,000 liters, we will consider expanding facilities in the United States or Europe, depending on favorable business conditions.”

Celltrion is also strengthening its capabilities in new business areas. The company is focusing on developing next-generation drug pipelines, particularly in antibody-drug conjugates (ADCs) and multi-specific antibodies. Additionally, it is working on oral versions of autoimmune disease treatments Stelara and Humira.

The company has set a goal of launching 11 biosimilar products by next year and expanding its portfolio to 22 products, including biosimilars and novel drugs, by 2030.

Suh projected that Celltrion’s annual revenue for this year will reach KRW 3.5 trillion. As of the third quarter, the company has already achieved cumulative sales of KRW 2.4936 trillion, surpassing last year’s total annual revenue of KRW 2.1764 trillion. He predicted that revenue will grow to KRW 7–8 trillion by 2026 and reach KRW 10 trillion by 2027.

To enhance shareholder value, Celltrion  plans to continue share buybacks and cancellations. Suh revealed that the company currently holds 5% of its total issued shares as treasury stock, 25% of which will be canceled within this year. The remaining 75% will be used as investment capital, and the company plans to expand cash dividends to maximize shareholder returns.